Global Neurocognitive Disorder
Treatment Market: Market Dynamics
Increasing prevalence of
neurocognitive disorder is expected to augment the global Neurocognitive
Disorder Treatment Market growth. Due to advancement in technology and
inventions such as Al and adoption of unhealthy work practices, increased
cardiovascular issues are boosting the global neurocognitive disorder market.
Moreover, increased addiction of drugs and alcohol in youth and also changing
climate conditions or respiratory diseases are causing neurocognitive disorders
and driving the market growth. Furthermore, increase in number of geriatric
population is also the factor affecting the market growth. Approvals of the
drugs associated with the treatment from the regulatory bodies is the factor
that drives the market growth. For instance, on April 11, 2019, the U.S.FDA
accepted the resubmitted new drug application (NDA) for instradefylline
(KW-6002), which is an oral selective adenosine receptor antagonist for use as
adjunctive treatment for Parkinson’s disease in adults. On May 20, 2019, the
U.S.FDA approved Neuronascent Investigational New Drug (IND) application for
NNI-362.
The clinical trials of some drugs
are terminated, as they are not able to reach to their primary endpoint. For
instance, on March 21, 2019, Biogen and Eisei, Co., Ltd announced the decision
to discontinue the global phase 3 trial of Aducanumab, which is designed to
evaluate the safety and efficacy of an antibody-aducanumab in patients with
Alzheimer disease. This decision to stop the trial is based on the analysis
that trials were unlikely to improve the people’s memory and thinking
sufficiently by the end of the trial. This discontinuation of trials is the
major restraining factor for the market.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2676
Neurocognitive disorders include
dementia, delirium, and mild cognitive impairment, which is characterized by
decline of the level of cognitive functioning. Neurocognitive deficit is a
reduction or impairment of cognitive functions and affects nerve cells and
often impact the person’s ability to remember, to reason, and to make
judgments. The neurocognitive disorders have different clinical characteristics
with Alzheimer disease, front temporal degeneration, cerebrovascular disease,
traumatic brain injury, Lewy body disease, and infections showing the common
causes. Alzheimer disease is the most common cause of neurocognitive disorder.
In the early stages of Alzheimer, people are not able to remember the recent
events, conversations, and names of people and may also experience the
depression. Individuals with neurocognitive disorder show the side effects like
mood disturbances including apathy, depression, anxiety and sleep disturbance including
insomnia, hypersomnia.
Neurocognitive disorder treatments
include pain medications, surgeries, physical therapy, bed rest, and others.
Furthermore, for treatment of neurocognitive disorder, antibiotics are used to
clear the remaining infections, which is affecting the brain, such as
meningitis.
Global Neurocognitive Disorder
Treatment Market: Regional Dynamics
North America is expected to hold
a dominant position in the global neurocognitive disorder treatment market,
owing to adoption of advanced technology and rising number of neurocognitive
disorder patients. According to the World Health Organization (WHO), nearly
35.6 million people live with dementia worldwide. The number of geriatric
population worldwide and related dementia patients is expected to rise up to
65.7 million in 2030 and 115.4million in 2050. Furthermore, according WHO, the
prevalence of dementia is increasing exponentially with age and sex in North
America region, doubling in every 5.5 years. Moreover, satisfactory
reimbursement policies, rising adoption of advance precautious methods and
increasing penetration of life science analytics for monitoring health changes
continuously are factors driving the growth of market in North America.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/neurocognitive-disorder-treatment-market-2676
Global Neurocognitive Disorder
Treatment Market: Competitive Landscape
The key players in global
neurocognitive disorder treatment market are focusing on developing innovative,
new, and efficient neurocognitive disorder treatment drugs that are launched in
the market to meet the demand from consumers for various types of
neurocognitive disorder treatments. For instance, in March 2018, Biogen
announced to enter into an agreement to acquire Pfizer Inc. phase 2b ready AMPA
receptor potentiator for cognitive impairment.
Furthermore, in May 2019, T3D
therapeutics received grant of US$ 9 million from National Institute on Aging
(NIA) to develop drug T3D-959 for neurocognitive disease.
Key players operating in the
global neurocognitive disorder treatment market include A B Science, Abbive, A
C immune, Biogen, Eisai, Immunobrain, Mediti Pharma Inc., Ono Pharmaceuticals,
Proclar Biosciences, Problodrug AG, Roche, T3D Therapeutics, and Purdue
Pharma.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2676
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to emerging
market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment